Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3853

Sort by

Sort Order Select

Journal Articles

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Blood (2021) 138 (7): 507–519.

https://doi.org/10.1182/blood.2021011103

Published: 2021

Includes: Supplemental data

Journal Articles

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Blood (2021) 137 (22): 3093–3104.

https://doi.org/10.1182/blood.2020007626

Published: 2021

Includes: Supplemental data

Journal Articles

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

Semjon Willier, Paula Rothämel, Maximilian Hastreiter, Jonas Wilhelm, Dana Stenger, Franziska Blaeschke, Meino Rohlfs, Theresa Kaeuferle, Irene Schmid, Michael H. Albert, Vera Binder, Marion Subklewe, Christoph Klein, Tobias Feuchtinger

Blood (2021) 137 (8): 1037–1049.

https://doi.org/10.1182/blood.2020006921

Published: 2021

Includes: Supplemental data

Journal Articles

How I diagnose and treat NPM1 -mutated AML

Brunangelo Falini, Lorenzo Brunetti, Maria Paola Martelli

Blood (2021) 137 (5): 589–599.

https://doi.org/10.1182/blood.2020008211

Published: 2021

Journal Articles

Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia

Michael Pepper, Brent Tan

Blood (2020) 136 (12): 1467.

https://doi.org/10.1182/blood.2020007198

Published: 2020

Journal Articles

How I treat relapsed or refractory AML

Susan DeWolf, Martin S. Tallman

Blood (2020) 136 (9): 1023–1032.

https://doi.org/10.1182/blood.2019001982

Published: 2020

Journal Articles

13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking

Minjun Yang, Setareh Safavi, Eleanor L. Woodward, Nicolas Duployez, Linda Olsson-Arvidsson, Jonas Ungerbäck, Mikael Sigvardsson, Marketa Zaliova, Jan Zuna, Thoas Fioretos, Bertil Johansson, Karolin H. Nord, Kajsa Paulsson

Blood (2020) 136 (8): 946–956.

https://doi.org/10.1182/blood.2019004684

Published: 2020

Includes: Supplemental data

Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Blood (2020) 135 (17): 1472–1483.

https://doi.org/10.1182/blood.2019003538

Published: 2020

Includes: Supplemental data

Journal Articles

Co-occurrence of DNMT3A , NPM1 , FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis

Blood (2020) 135 (11): 870–875.

https://doi.org/10.1182/blood.2019003339

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Blood (2020) 135 (5): 371–380.

https://doi.org/10.1182/blood.2019002697

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo, Andrew H. Wei

Blood (2020) 135 (2): 85–96.

https://doi.org/10.1182/blood.2019001239

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT

Julian Borrow, Sara A. Dyer, Susanna Akiki, Michael J. Griffiths

Blood (2019) 134 (25): 2291–2303.

https://doi.org/10.1182/blood.2019001240

Published: 2019

Includes: Supplemental data

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

Targeting Critical Kinases and Anti-Apoptotic Molecules Overcomes Steroid Resistance in Infant MLL-Rearranged Leukemia

Anne Pieta De Groot, Yoriko Saito, MD, Eiryo Kawakami, Mari Hashimoto, Yuki Aoki, Rintaro Ono, MD PhD, Ikuko Ogahara, Saera Fujiki, Akiko Kaneko, Takashi Watanabe, PhD, Masatoshi Takagi, MD PhD, Daisuke Tomizawa, MD PhD, Katsuyoshi Koh, MD, Mariko Eguchi, MD, Eiichi Ishii, MD PhD, Osamu Ohara, Leonard Shultz, PhD, Shuki Mizutani, Fumihiko Ishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 3885.

https://doi.org/10.1182/blood-2019-129719

Published: 2019

Journal Articles

The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients

Francesca Ferraro, MD PhD, Christopher A Miller, PhD, Amy Abdalla, Nichole Helton, Nathan Salomonis, PhD, Robert S Fulton, Catrina Fronick, BS, Sharon E Heath, Peter Westervelt, MD PhD, Timothy J Ley, MD

Blood (2019) 134 (Supplement_1): 3827.

https://doi.org/10.1182/blood-2019-122967

Published: 2019

Journal Articles

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Blood (2019) 134 (Supplement_1): 3828.

https://doi.org/10.1182/blood-2019-131303

Published: 2019

Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood (2019) 134 (Supplement_1): 3891.

https://doi.org/10.1182/blood-2019-127187

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

NARROW

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

How I diagnose and treat NPM1 -mutated AML

Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia

How I treat relapsed or refractory AML

13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Co-occurrence of DNMT3A , NPM1 , FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

How I treat acute myeloid leukemia in the era of new drugs

Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Targeting Critical Kinases and Anti-Apoptotic Molecules Overcomes Steroid Resistance in Infant MLL-Rearranged Leukemia

The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only